Patents by Inventor Su-Ming Chiang
Su-Ming Chiang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20050238705Abstract: The invention provides lipid-based dispersion comprising comprising, a) phosphatidyl choline; b) an anionic phospholipid; optionally c) up to 1% cholesterol by weight of total lipids; and optionally d) a therapeutic agent; wherein the mean particle size measured by dynamic light scattering is less than 100 nm. The invention also provides pharmaceutical compositions comprising such a dispersion as well as methods of producing a therapeutic effect in a mammal comprising administering an effective amount of such a dispersion.Type: ApplicationFiled: January 14, 2005Publication date: October 27, 2005Inventors: Ning Hu, Gerard Jensen, Stephanie Yang, Su-Ming Chiang
-
Publication number: 20040175417Abstract: A novel composition and method for solubilizing amphiphilic drugs in a small amount of organic solvent for use in improved liposomes is disclosed. A phosphatidylglycerol is acidified in a small amount of organic solvent. The amphiphilic drug, such as Amphotericin B, suspended in organic solvent is then added to the acidified phosphatidylycerol and a soluble complex is formed between the phosphatidylglycerol and the amphiphilic drug. When the liposome composition incorporating the soluble complex is hydrated, the final pH of the hydrating aqueous buffer is carefully controlled. The Amphotericin B liposomes formed have markedly reduced toxicity.Type: ApplicationFiled: March 17, 2004Publication date: September 9, 2004Applicant: GILEAD SCIENCES, INC.Inventors: Richard T. Proffitt, Jill Adler-Moore, Su-Ming Chiang
-
Publication number: 20040156888Abstract: The invention provides a formulation comprising a lipophobic therapeutic agent encapsulated in a liposome having improved efficacy and/or reduced toxicity.Type: ApplicationFiled: November 26, 2003Publication date: August 12, 2004Inventors: Gerard M. Jensen, Ning Hu, Su-Ming Chiang, Craig Skenes, Richard Fahrner
-
Patent number: 6770290Abstract: A novel composition and method for solubilizing amphiphilic drugs in a small amount of organic solvent for use in improved liposomes is disclosed. A phosphatidylglycerol is acidified in a small amount of organic solvent. The amphiphilic drug, such as Amphotericin B, suspended in organic solvent is then added to the acidified phosphatidylycerol and a soluble complex is formed between the phosphatidylglycerol and the amphiphilic drug. When the liposome composition incorporating the soluble complex is hydrated, the final pH of the hydrating aqueous buffer is carefully controlled. The Amphotericin B liposomes formed have markedly reduced toxicity.Type: GrantFiled: October 19, 1990Date of Patent: August 3, 2004Assignee: Gilead Sciences, Inc.Inventors: Richard T. Proffitt, Jill Adler-Moore, Su-Ming Chiang
-
Patent number: 6740335Abstract: Liposomal encapsulated camptothecin formulations are provided. The liposomes have improved pharmacokinetics, enhanced efficacy as anti-tumor agents and provide an increased therapeutic index as compared to the free drug and topotecan. The formulations include liposomes comprising at least one phospholipid and a camptothecin or analog thereof.Type: GrantFiled: February 24, 2000Date of Patent: May 25, 2004Assignee: OSI Pharmaceuticals, Inc.Inventors: Karen Lewis Moynihan, David Lloyd Emerson, Su-Ming Chiang, Ning Hu
-
Publication number: 20040057990Abstract: Liposomal encapsulated benzoquinazoline thymidylate synthase inhibitor formulations are provided. The liposomes have improved pharmacokinetics and enhanced efficacy as anti-tumor agents compared to the free drug. The formulations include liposomes comprising at least one phosphatidylcholine, a cholesterol, and a benzoquinazoline thymidylate synthase inhibitor.Type: ApplicationFiled: July 1, 2003Publication date: March 25, 2004Applicant: OSI Pharmaceuticals, Inc.Inventors: Claudine S. Ashvar, Su-Ming Chiang, David L. Emerson, Ning Hu, Gerard M. Jensen
-
Patent number: 6689381Abstract: Liposomal encapsulated benzoquinazoline thymidylate synthase inhibitor formulations are provided. The liposomes have improved pharmacokinetics and enhanced efficacy as anti-tumor agents compared to the free drug. The formulations include liposomes comprising at least one phosphatidylcholine, a cholesterol, and a benzoquinazoline thymidylate synthase inhibitor.Type: GrantFiled: June 6, 2001Date of Patent: February 10, 2004Assignee: OSI Pharmaceuticals, Inc.Inventors: Claudine S. Ashvar, Su-Ming Chiang, David L. Emerson, Ning Hu, Gerard M. Jensen
-
Publication number: 20020034538Abstract: Liposomal encapsulated benzoquinazoline thymidylate synthase inhibitor formulations are provided. The liposomes have improved pharmacokinetics and enhanced efficacy as anti-tumor agents compared to the free drug. The formulations include liposomes comprising at least one phosphatidylcholine, a cholesterol, and a benzoquinazoline thymidylate synthase inhibitor.Type: ApplicationFiled: June 6, 2001Publication date: March 21, 2002Applicant: GILEAD SCIENCES, INC.Inventors: Claudine S. Ashvar, Su-Ming Chiang, David L. Emerson, Ning Hu, Gerard M. Jensen
-
Patent number: 6221388Abstract: A liposomal aminoglycoside formulation comprising a neutral lipid, a negatively charged lipids and a sterol. The formulation contains unilamellar vesicles having an average size below 100 nm. A process of making liposomes containing an aminoglycoside is also provided. A method is also provided for the treatment of drug susceptible and drug resistant bacteria.Type: GrantFiled: September 28, 1999Date of Patent: April 24, 2001Assignee: Gilead Sciences, Inc.Inventors: Evan M. Hersch, Eskild A. Petersen, Richard T. Proffitt, Kevin R. Bracken, Su-Ming Chiang
-
Patent number: 5965156Abstract: A novel composition and method for solubilizing amphiphilic drugs in a small amount of organic solvent for use in improved liposomes is disclosed. A phosphatidylglycerol is acidified in a small amount of organic solvent. The amphiphilic drug, such as Amphotericin B, suspended in organic solvent is then added to the acidified phosphatidylycerol and a soluble complex is formed between the phosphatidylglycerol and the amphiphilic drug. When the liposome composition incorporating the soluble complex is hydrated, the final pH of the hydrating aqueous buffer is carefully controlled. The Amphotericin B liposomes formed have markedly reduced toxicity.Type: GrantFiled: June 6, 1995Date of Patent: October 12, 1999Assignee: NeXstar Pharmaceuticals, Inc.Inventors: Richard T. Proffitt, Jill Adler-Moore, Su-Ming Chiang
-
Patent number: 5958449Abstract: A liposomal aminoglycoside formulation comprising a neutral lipid, a negatively charged lipid and a sterol. The formulation contains unilamellar vesicles having an average size below 100 nm. A process of making liposomes containing an aminoglycoside is provided. A method is also provide for the treatment of drug susceptible and drug resistant bacteria.Type: GrantFiled: May 21, 1998Date of Patent: September 28, 1999Assignee: NeXstar Pharmaceuticals, Inc.Inventors: Evan M. Hersch, Eskild A. Petersen, Richard T. Proffitt, Kevin R. Bracken, Su-Ming Chiang
-
Patent number: 5759571Abstract: A liposomal aminoglycoside formulation comprising a neutral lipid, a negatively charged lipids and a sterol. The formulation contains unilamellar vesicles having an average size below 100 nm. A process of making liposomes containing an aminoglycoside is provided where the hydration temperature is significantly below the transition temperature of the formulation. A method for the treatment of drug susceptible and drug resistant bacteria.Type: GrantFiled: June 23, 1993Date of Patent: June 2, 1998Assignee: NeXstar Pharmaceuticals, Inc.Inventors: Evan M. Hersch, Eskild A. Petersen, Richard T. Proffitt, Kevin R. Bracken, Su-Ming Chiang
-
Patent number: 5756120Abstract: A liposomal aminoglycoside formulation comprising a neutral lipid, a negatively charged lipids and a sterol. The formulation contains unilamellar vesicles having an average size below 100 nm. A process of making liposomes containing an aminoglycoside is provided where the hydration temperature is significantly below the transition temperature of the formulation. A method for the treatment of drug susceptible and drug resistant bacteria.Type: GrantFiled: June 6, 1995Date of Patent: May 26, 1998Assignee: NeXstar Pharmaceuticals, Inc.Inventors: Evan M. Hersch, Eskild A. Petersen, Richard T. Proffitt, Kevin R. Bracken, Su-Ming Chiang
-
Patent number: 5683714Abstract: An improved liposomal cyclosporin therapeutic formulation, comprising phosphatidylcholine, phosphatidylglycerol and a cyclosporin in a mole ratio of from 25:3:1 to 17:3:1 is described. The formulation includes unilamellar vesicles having reduced toxicity. The formulation is used as an immunosuppressive agent and is an enhancer of the efficacy of antineoplasties for drug resistant cancer cells. A method is also provided for inhibiting the growth of cancer cells.Type: GrantFiled: April 5, 1995Date of Patent: November 4, 1997Assignee: NeXstar Pharmaceuticals, Inc.Inventors: Jill P. Adler-Moore, Su-Ming Chiang
-
Patent number: 5656287Abstract: An improved liposomal cyclosporin therapeutic formulation, comprising phosphatidylcholine, cholesterol, dimyristoylphosphatidylglycerol and a cyclosporin in a mole ratios of about 21:0.5:3:1 to 21:1.5:3:1 and 24:0.5:3:1 to about 24:1.5:3:1. The formulations are useful as immunosuppressive agents and enhancers of antineoplastic agents in drug resistant cancer cells.Type: GrantFiled: June 7, 1995Date of Patent: August 12, 1997Assignee: NeXstar Pharmaceuticals, Inc.Inventors: Jill Adler-Moore, Su-Ming Chiang